Related Experiment Video
Updated: Jun 16, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
End points of therapy in chronic hepatitis B
Si Nafa Si Ahmed1, Marie Ecochard, Fabien Zoulim
1INSERM, U871, 69003 Lyon, France.
Expert Review of Gastroenterology & Hepatology
|February 9, 2010
Summary
This review examines clinical, histological, biochemical, and virological endpoints for chronic hepatitis B (CHB) management. It discusses treatment goals, survival benefits, and the potential of surrogate criteria for assessing therapy efficacy in CHB.
Area of Science:
- Hepatology and Viral Gastroenterology
- Clinical Trial Design and Endpoint Analysis
Background:
- Chronic hepatitis B (CHB) management relies on various clinical, histological, biochemical, and virological endpoints.
- Understanding the impact and variation of these endpoints is crucial for assessing disease course and treatment outcomes.
- Current treatment goals focus on improving patient survival and quality of life.
Purpose of the Study:
- To review the relevance and definitions of clinical, histological, biochemical, and virological endpoints in CHB.
- To evaluate the potential of surrogate endpoints used in clinical trials as accurate measures of treatment efficacy.
- To discuss the development of novel clinical endpoints in light of advanced antiviral therapies for CHB.
Main Methods:
- Comprehensive literature review of studies assessing endpoints in chronic hepatitis B.
- Analysis of treatment outcomes based on established and proposed endpoints.
- Evaluation of surrogate criteria for predicting long-term outcomes like cirrhosis and hepatocellular carcinoma.
Main Results:
- Prevention of disease progression to cirrhosis, decompensated cirrhosis, end-stage liver disease, and hepatocellular carcinoma is key for survival.
- Established endpoints are often long-term, necessitating the analysis of surrogate criteria for clinical trial efficiency.
- Therapeutic results require careful analysis against approved endpoints and their impact on CHB management.
Conclusions:
- Optimizing survival in CHB involves preventing disease progression through effective management strategies.
- Surrogate endpoints show promise but require validation to accurately reflect treatment efficacy in clinical trials.
- The development of new, more sensitive clinical endpoints is essential for evaluating potent antiviral therapies.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...